SEC Form 4: Bradley Mark T. covered exercise/tax liability with 7,789 units of Ordinary Shares, decreasing direct ownership by 8% to 87,408 units (for tax liability)

$ENDP
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ENDP alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Bradley Mark T.

(Last) (First) (Middle)
C/O ENDO INTERNATIONAL PLC
FIRST FL, MINERVA HOUSE, SIMMONSCOURT RD

(Street)
BALLSBRIDGE, DUBLIN L2

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Endo International plc [ ENDP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/05/2022
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 03/05/2022(1) F 7,789(2) D $2.3425(3) 87,408 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Thirty-three and one-third percent (33 1/3%) of Mr. Bradley's March 5, 2021 grant of restricted stock units (RSUs) vested on March 5, 2022.
2. These shares represent stock withheld by Endo International plc to satisfy Mr. Bradley's tax withholding obligations on shares acquired upon vesting of RSUs.
3. Represents the vesting price which is the average of the high and low share price on March 4, 2022, the last trading day prior to vesting.
Remarks:
/s/ Matthew J. Maletta, by power of attorney 03/08/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $ENDP alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ENDP

DatePrice TargetRatingAnalyst
5/6/2022$3.00 → $1.00Neutral → Underweight
Piper Sandler
3/9/2022$11.00 → $6.00Buy
Citigroup
3/2/2022$5.00 → $3.00Neutral
Piper Sandler
3/2/2022$5.00 → $2.00Equal-Weight → Underweight
Barclays
12/16/2021$7.00 → $5.00Equal-Weight
Barclays
8/31/2021$10.00 → $3.00Overweight → Neutral
Piper Sandler
8/9/2021$6.00 → $5.00Sector Perform
RBC Capital
More analyst ratings

$ENDP
Press Releases

Fastest customizable press release news feed in the world

See more
  • C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

    MONTREAL, June 12, 2023 /CNW/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sensitivit

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • C3i partners with Paladin Labs Inc. to offer Canadian clinicians a complimentary testing service to detect T315I mutation

    MONTREAL, June 12, 2023 /PRNewswire/ - C3i Center Inc and Paladin Labs Inc., a subsidiary of Endo International plc (NASDAQ:ENDP), have partnered to launch a complimentary clinical testing program for the diagnosis of the T315I mutation in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) patients in Canada. "We're pleased to be working with Paladin Labs to offer this innovative and important testing program that will provide physicians and patients with additional information to guide treatment decisions," says Dr Lambert Busque, Chief Medical Officer of C3i. "Digital PCR (ddPCR) technology can identify the T315I mutation with a sen

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation

    Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will Continue to Receive Highest Quality Products and Excellent Service Ample Liquidity to Fund Day-to-Day Operations and Ordinary Course Investments During Court-Supervised Process DUBLIN, Aug. 16, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) ("Endo" or the "Company") today announced that it has entered into a restructuring support agreement ("RSA") with holders of more than a majority of Endo's first lien debt on a sale transaction that would substantially reduce outstanding indebted

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENDP
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ENDP
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ENDP
SEC Filings

See more

$ENDP
Leadership Updates

Live Leadership Updates

See more
  • Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development

    DUBLIN, Jan. 11, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today announced the appointment of Dr. James P. Tursi as Executive Vice President, Global Research & Development effective January 18, 2022.  He will join the Company's Senior Executive Team and report directly to the Chief Executive Officer. Prior to joining Endo, Dr. Tursi held the role of Chief Scientific Officer and Executive Vice President of Development at Ferring Pharmaceuticals U.S. "Dr. Tursi is a proven leader with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience," said Blaise Coleman, Endo's President and Chief Executive Officer. "His broad therapeutic expertis

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Endo Appoints Jennifer M. Chao to Board of Directors

    DUBLIN, Feb. 17, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately.  Ms. Chao has also been appointed to Endo's Audit Committee and its Compliance Committee and becomes the eighth independent director on Endo's expanded ten member Board.  Ms. Chao will stand for election by Endo's shareholders at the Company's 2021 Annual General Meeting. Continue Reading Jennifer M. Chao Ms. Chao has over 25 years of experience in the biotech and life sciences industries focused primarily on finance and corporate strategy.  She is the founder

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • POINT Biopharma Announces New Board Appointments

    Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour join POINT’s Board of Directors TORONTO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced the appointment of Jonathan Ross Goodman, Gerry Hogue and Peggy Gilmour to its Board of Directors. Mr. Goodman was the co-founder, President and CEO of publicly-traded Paladin Labs Inc (TSE:PLB), which was acquired in 2014 by Endo International Inc. (NASDAQ:ENDP) for $3.2 billion. The same day that Paladin was sold, Mr. Goodman started a second publicly-traded specialty pharmaceutical company, Kn

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENDP
Financials

Live finance-specific insights

See more
  • ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

    DUBLIN, May 5, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. "Despite challenging market dynamics for VASOSTRICT®, our first-quarter financial performance was in-line with our expectations with growth in our Branded Specialty Products portfolio driven by XIAFLEX® and our Generics segment driven by varenicline, the only FDA approved generic for Chantix®," said Blaise Coleman, Endo's President and Chief Executive Officer. "As we manage thro

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar

    DUBLIN, May 2, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc. "These six product candidates that would be used in critical care settings meaningfully expand Endo's ready-to-use injectable product pipeline," said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. "We look forward to further developing and bringing these durabl

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Endo to Announce First-Quarter 2022 Financial Results

    DUBLIN, April 12, 2022 /PRNewswire/ -- Endo International plc (NASDAQ:ENDP) will announce its first–quarter 2022 financial results on May 5, 2022 and members of its senior management team will host a conference call and webcast on May 6, 2022 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 8947159. Please dial in 10 minutes prior to the scheduled start time. A replay of the call will be available from May 6, 2022 at 10:30 a.m. ET until 9:30 a.m. ET on May

    $ENDP
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ENDP
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more